Ocular Therapeutix Inc (NASDAQ:OCUL) currently has a daily average trading volume of 892.08K but it saw 1543810 shares traded in last market. With a market cap of 1.22B USD, the company’s current market price of $7.78 came falling about -0.77 while comparing to the previous closing price of $7.84. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.77 and as low as $4.06. In the recent trading on the day, stock has struck highest price mark of $7.615 while lowest mark touched by it was $8.04.
Taking a look at 20-day trading activity of Ocular Therapeutix Inc (OCUL) gives us an average price of $8.23, while its current price level is -33.93% below from 52-week high level whereas it is 91.63% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.71 while that of 200 days or SMA-200 reads an average of $8.07. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.32% during that period while stretching the period over a month that increases to 4.40%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 34.87 which implies that the stock is in neutral territory.
TD Cowen upgraded its recommendation for the stock as a “Buy” from “Hold” on June 20, 2024 while assigning a price target range of $7-$11. Piper Sandler issued its recommendations for the stock as it resumed the price target for the stock is $15.
Over the week, OCUL’s stock price is moving -2.51% down while it is -7.82% when we observe its performance for the past one month. Year-to-date it is -8.90% down and over the past year, the stock is showing an upside performance of 52.25%.
Currently, Ocular Therapeutix Inc’s total number of outstanding shares is 156.65M with 1.06% of that held by the insiders while 91.08% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -40.98% and return on equity (ROE) at -96.89%. Stock’s beta reads 1.22. Stock has a price to book (P/B) ratio of 3.46 while price to sale or P/S ratio amounts to 19.91. Its return on asset (ROA) is -53.42% on average.
